91
Participants
Start Date
February 24, 2022
Primary Completion Date
May 11, 2023
Study Completion Date
May 11, 2023
AVTX-002
Dose of 600 mg administered subcutaneously three times during the study.
Placebo
Placebo sourced as normal saline administered subcutaneously three times during the study.
Continental Clinical Solutions, LLC, Towson
Clinical Research Partners, LLC, Richmond
Meridian Clinical Research, Portsmouth
Pro-Care Research Center, Corp., Miami Gardens
Suncoast Research Group LLC, Miami
Suncoast Research Associates LLC, Miami
Innovation Medical Research Center, Palmetto Bay
Helix Biomedics, LLC, Boynton Beach
Affinity Health, Nashville
Family Allergy and Asthma Research Institute, Louisville
ASHA Clinical Research-Munster, LLC, Hammond
Pulmonary Research Institute of Southeast Michigan, Farmington Hills
Midwest Clinical Research, St Louis
Meridian Clinical Research, Lincoln
OK Clinical Research, Edmond
Pioneer Research Solutions, Houston
South Texas Medical Research Institute, Inc, Boerne
Amarillo Center For Clinical Research, Amarillo
IMMUNOe Research Centers, Centennial
National Jewish Health, Denver
Tucson Neuroscience Research - M3, Wake Research, Tucson
Allergy and Asthma Medical Group of the Bay Area, Walnut Creek
Center For Clinical Trials of Sacramento, Sacramento
Center For Clinical Trials of San Gabriel, West Covina
Lead Sponsor
Avalo Therapeutics, Inc.
INDUSTRY